Adverum Stock Falls As It Stops Testing Ocular Gene Therapy Candidate In Diabetic Macular Edema Patients

Adverum Biotechnologies Inc (NASDAQ:ADVM) has decided to drop the development of ADVM-022 intravitreal (IVT) injection gene therapy in diabetic macular edema (DME) after dose-limiting toxicity (DLT) was observed at the high dose (6 x 10^11 vg/eye) in patients with DME.
In April, Adverum's stock plunged after a Suspected Unexpected Serious Adverse Reaction of decreased ocular pressure was reported in one patient in the high-dose cohort of the INFINITY Phase 2 trial.
After that disclosure, it immediately unmasked the trial and monitored all patients who received a single high dose of ADVM-022.
Additional patients treated with a single high dose of ADVM-022 experienced decreased intraocular pressure refractory to steroids and required subsequent additional treatment.
These events occurred 16-36 weeks after treatment with the high dose. No similar events have been observed in DME patients treated with the low dose or to date in any wet age-related macular degeneration (wet AMD) patients.
Now, the company is planning to evaluate ADVM-022 at low doses (2 x 10^11 vg/eye and lower) and alternative prophylactic regimens in future Phase 2 trial in wet AMD.
It plans to present long-term OPTIC data in wet AMD in 2H21, including 52-week data from Cohort 4 (high dose of 6 x 10^11 vg/eye with steroid eye drop prophylaxis, n=9), at a medical conference.
Analyst Reaction: SVB Leerink lowered the price target from $5 to $2 but maintained a Market Perform rating.
Price Action: ADVM Shares are down 21.6% at $2.40 during the premarket session on the last check Friday.

Market News and Data brought to you by Benzinga APIs

To add Benzinga News as your preferred source on Google, click here.